Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS ...Middle East

PR Newswire - News
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
CARLSBAD, Calif., April 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral sclerosis (ALS) with mutations in the fused in sarcoma gene (FUS). Patients with a mutation...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS )

Apple Storegoogle play

Also on site :